Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$36.75 USD

36.75
270,338

-0.37 (-1.00%)

Updated Aug 27, 2026 04:00 PM ET

After-Market: $36.80 +0.05 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

by Zacks Equity Research

Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.

Zacks Equity Research

Alkermes' Q1 Earnings and Revenues Fall Short of Estimates

by Zacks Equity Research

ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.

Zacks Equity Research

Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

by Zacks Equity Research

AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.

Zacks Equity Research

Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 107.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

by Zacks Equity Research

RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.

Zacks Equity Research

Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?

by Zacks Equity Research

Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

by Zacks Equity Research

Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.

Zacks Equity Research

United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat

by Zacks Equity Research

UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates. Stock down in pre-market trading.

Zacks Equity Research

Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales

by Zacks Equity Research

BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.

Zacks Equity Research

Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.